Polo-like kinases (PLKs) have been reported to be essential components of anti-viral pathways. However, the role of PLKs in the production of pro-inflammatory cytokines induced by TLR activation is uncertain. We report here that monocytic THP-1 cells expressed PLK1, PLK2, PLK3 and PLK4. When THP-1 cells were treated with GW843682X, an inhibitor of PLK1 and PLK3, the results showed that GW843682X down-regulated Pam3CSK4- and LPS-induced TNF-α at both the gene and protein levels. GW843682X did not impact Pam3CSK4-induced IL-1β and IL-8 or LPS-induced IL-1β, but it down-regulated LPS-induced IL-8 significantly. Moreover, western blot results showed that TLRs activated PLK1, and PLK1 inhibition by RNA interference down-regulated Pam3CSK4-induced TNF-α production, suggesting the involvement of PLK1 in TNF-α up-regulation. In addition, GW843682X treatment for 12 to 24 h induced cell death and down-regulated MyD88, but neither of these roles contributed to the down-regulation of TNF-α, as TNF-α gene expression was up-regulated at 1 h. Furthermore, GW843682X inhibited Pam3CSK4-induced activation of ERK and NF-κB, which contributed to Pam3CSK4-induced up-regulation of TNF-α. GW843682X also inhibited LPS-induced activation of ERK, p38 and NF-κB, which contributed to LPS-induced up-regulation of TNF-α. Taken together, these results suggested that PLK1 is involved in TLR2- and TLR4-induced inflammation, and GW843682X may be valuable for the regulation of the inflammatory response.
References
[1]
Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384. doi:10.1038/ni.1863. PubMed: 20404851.
[2]
Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140: 805-820. doi:10.1016/j.cell.2010.01.022. PubMed: 20303872.
[3]
Hou B, Reizis B, DeFranco AL (2008) Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 29: 272-282. doi:10.1016/j.immuni.2008.05.016. PubMed: 18656388.
[4]
Manicassamy S, Pulendran B (2009) Modulation of adaptive immunity with Toll-like receptors. Semin Immunol 21: 185-193. doi:10.1016/j.smim.2009.05.005. PubMed: 19502082.
Gao C, H？lscher C, Liu Y, Li L (2011) GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 23: 1-11. PubMed: 22718609.
[7]
Martin M, Rehani K, Jope RS, Michalek SM (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784. doi:10.1038/ni1221. PubMed: 16007092.
[8]
Woodgett JR, Ohashi PS (2005) GSK3: an in-Toll-erant protein kinase? Nat Immunol 6: 751-752. doi:10.1038/nrm1758. PubMed: 16034428.
[9]
Ma L, Dong F, Zaid M, Kumar A, Zha X (2012) ABCA1 Protein Enhances Toll-like Receptor 4 (TLR4)-stimulated Interleukin-10 (IL-10) Secretion through Protein Kinase A (PKA) Activation. J Biol Chem 287: 40502-40512. doi:10.1074/jbc.M112.413245. PubMed: 23055522.
[10]
Zhang Q, Wang C, Liu Z, Liu X, Han C et al. (2012) Notch signal suppresses Toll-like receptor-triggered inflammatory responses in macrophages by inhibiting extracellular signal-regulated kinase 1/2-mediated nuclear factor kappaB activation. J Biol Chem 287: 6208-6217. doi:10.1074/jbc.M111.310375. PubMed: 22205705.
[11]
Steiner TS, Ivison SM, Yao Y, Kifayet A (2010) Protein kinase D1 and D2 are involved in chemokine release induced by toll-like receptors. p. 2, 4, and 5. Cell Immunol 264: 135-142.
[12]
Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6: 321-330. doi:10.1038/nrc1841. PubMed: 16557283.
[13]
Chevrier N, Mertins P, Artyomov MN, Shalek AK, Iannacone M et al. (2011) Systematic discovery of TLR signaling components delineates viral-sensing circuits. Cell 147: 853-867. doi:10.1016/j.cell.2011.10.022. PubMed: 22078882.
[14]
Sun R, Zhang Y, Lv Q, Liu B, Jin M et al. (2011) Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J Biol Chem 286: 15918-15928. doi:10.1074/jbc.M110.178798. PubMed: 21367858.
[15]
Xiao Z, Yang M, Lv Q, Wang W, Deng M et al. (2011) P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin-induced cell death. J Cell Biochem 112: 2257-2265. doi:10.1002/jcb.23144. PubMed: 21503959.
[16]
Martin BT, Strebhardt K (2006) Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle 5: 2881-2885. doi:10.4161/cc.5.24.3538. PubMed: 17172872.
[17]
Sp？nkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K (2002) Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 94: 1863-1877. doi:10.1093/jnci/94.24.1863. PubMed: 12488480.
[18]
Masuda Y, Nishida A, Hori K, Hirabayashi T, Kajimoto S et al. (2003) Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 22: 1012-1023. doi:10.1038/sj.onc.1206200. PubMed: 12592388.
[19]
Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM et al. (2009) Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 124: 578-588. doi:10.1002/ijc.23990. PubMed: 19004025.
[20]
Koida N, Ozaki T, Yamamoto H, Ono S, Koda T et al. (2008) Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 283: 8555-8563. doi:10.1074/jbc.M710608200. PubMed: 18174154.
[21]
Archambault V, Glover DM (2009) Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10: 265-275. doi:10.1038/nrm2653. PubMed: 19305416.
[22]
Eckerdt F, Yuan J, Strebhardt K (2005) Polo-like kinases and oncogenesis. Oncogene 24: 267-276. doi:10.1038/sj.onc.1208273. PubMed: 15640842.
[23]
Noman AS, Koide N, Hassan F, I IE-K, Dagvadorj J, et al (2009) Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun 15: 33-41. doi:10.1177/1753425908099317. PubMed: 19201823.
[24]
Du Q, Min S, Chen LY, Ma YD, Guo XL et al. (2012) Major stress hormones suppress the response of macrophages through down-regulation of TLR2 and TLR4. J Surg Res 173: 354-361. doi:10.1016/j.jss.2010.10.016. PubMed: 21109260.
[25]
Tao S, Zhu L, Lee P, Lee WM, Knox K et al. (2012) Negative control of TLR3 signaling by TICAM1 down-regulation. Am J Respir Cell Mol Biol 46: 660-667. doi:10.1165/rcmb.2011-0340OC. PubMed: 22205631.
[26]
Parsons SA, Greer PA (2006) The Fps/Fes kinase regulates the inflammatory response to endotoxin through down-regulation of TLR4, NF-kappaB activation, and TNF-alpha secretion in macrophages. J Leukoc Biol 80: 1522-1528. doi:10.1189/jlb.0506350. PubMed: 16959897.
[27]
Xia X, Cui J, Wang HY, Zhu L, Matsueda S et al. (2011) NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 34: 843-853. doi:10.1016/j.immuni.2011.02.022. PubMed: 21703539.
[28]
Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052-1060. doi:10.1038/ni1110. PubMed: 15334086.
